Maruti Suzuki India partners with HDFC Bank to offer flexible car finance schemes
The country's largest car maker Maruti Suzuki India on Thursday said it has partnered with HDFC Bank Ltd to offer flexible finance schemes for new car buyers
New Delhi: The country's largest car maker Maruti Suzuki India on Thursday said it has partnered with HDFC Bank Ltd to offer flexible finance schemes for new car buyers.
The schemes include flexi equated monthly installment (EMI) options under which a customer can avail low EMI for three months every year, up to 100 percent on-road funding and installments starting from Rs 899 per month, per lakh, for the first six months, Maruti Suzuki India (MSI) said in a statement.
Commenting on the partnership, MSI Executive Director Marketing and Sales Shashank Srivastava said, "this is an advantage to buyers who may face resource crunch amidst the COVID-19 lockdown."
He further said, "new car buyers can select from a host of schemes that will offer low down payment options and low EMIs. This would particularly help customers in the entry-level segments."
In addition, digital disbursement makes it more convenient for customers in current times, Srivastava added.
HDFC Bank Country Head for Retail Assets Arvind Kapil said the partnership would provide customized offerings to customers particularly during the ongoing COVID-19 pandemic.
"These are challenging times for the country and we believe it's the collective responsibility of all stakeholders to provide flexible offerings to customers," he added.
In view of the current social distancing norms and the need to reduce physical documentation, HDFC Bank would also be offering Maruti Suzuki customers the option of a post-approval digital disbursement, the statement said.
Severe, long-term fatigue, post-exertional malaise, pain and sleep problems are characteristic signs of the disease
Residents of Zhenghzhou's city centre cannot leave the area unless they have a negative Covid test and permission from authorities, and are advised not to leave their homes "unless necessary", the local government said.
iNCOVACC is the world’s first Intranasal vaccine for COVID to receive approval for the primary 2-dose schedule, and heterologous booster dose